Novartis1h
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...
Novartis13d
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2025 Annual General Meeting
Basel, March 7, 2025 – Novartis shareholders today agreed to the Board of Directors’ recommendations for all proposed resolutions at the company’s Annual General Meeting (AGM). A total of 1,693 ...
Novartis8d
Novartis named first-ever corporate pharmaceutical partner of the National Football League
The long-term, exclusive pharmaceutical category agreement is designed to turn fans' passion for the game into a commitment to better health Novartis sports partnership covers the NFL's marquee health ...
Novartis1d
Career Search
Explore opportunities with Novartis below.
Novartis4d
Novartis Indonesia
Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Novartis works closely with healthcare professionals around the world to support ...
Novartis1d
Career Search
Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.
Novartis6d
Career search
Job Title Sort ascending Business Location Site Date Posted （高级）区域市场经理 Regular, Full time Innovative Medicines China Hangzhou (Zhejiang Province) Mar 07, 2025 Analyst, Digital Regular, Full time ...